Abstract
Fungi, both endemic and opportunistic, continue to be recognized as increasingly frequent pulmonary pathogens. Better appreciation of their epidemiology and clinical course, as well as clarification of the roles of the newer triazoles and lipid formulations of amphotericin B in treatment, have occurred within the past few years. Both endemic and opportunistic fungal pulmonary pathogens are reviewed, with emphasis on recent therapeutic advances.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Catanzaro A: Fungal pneumonias. Curr Opin Pulmon Med 1997, 3:146–150.
Centers for Disease Control and Prevention: Coccidioidomycosis —Arizona, 1990–1995. MMWR 1996, 45:1069–1073.
Vasquez JE, Mehta JB, Agrawal R, et al.: Blastomycosis in northeast Tennessee. Chest 1998, 114:436–443.
Denning DW: Invasive aspergillosis. Clin Infect Dis 1998, 26:781–805. An excellent state-of-the-art clinical article on the entire spectrum on invasive aspergillosis from its history to its treatment and outcome.
Bradsher RW: Histoplasmosis and blastomycosis. Clin Infect Dis 1996 May, 22(Suppl 2):S102-S111.
Meals LT, McKinney WP: Acute pulmonary histoplasmosis: Progressive pneumonia resulting from high inoculum exposure. Kentucky Med Assoc 1998, 96:258–260.
Tayor ML, Perez-Mejia A, Yamamoto-Furusho JK, Granados J: Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico. Mycopathologia 1997, 138:137–142.
Sarosi GA, Davies SF: Endemic mycosis complicating human immunodeficiency virus infection [conferences and reviews]. West J Med 1996, 164:335–340. A wonderful review of the three major endemic fungi in the United States (histoplasmosis, blastomycosis, coccidioidomycosis). It takes a close look at these pathogenic fungi from their epidemiology all the way to diagnosis and treatment.
Shelhamer JH, Gill VJ, Quinn TC, et al.: The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996, 124:585–599.
Kauffman CA: Role of azoles in antifungal therapy. Clin Infect Dis 1996, 22(Suppl 2):S148-S153.
Wheat J: Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997 76:339–354.
McKinsey DS, Kauffman CA, Pappas PG, et al.: Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1996 23:996–1001.
Wheaton J: Histoplasmosis: recognition and treatment [review]. Clin Infect Dis 1994, 19 (Suppl 1):S19-S27.
Wheat J, Hafner R, Korzun AH, et al.: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995, 98(4):336–342.
Wheat J, MaWhinney S, Hafner R, et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997 103:223–232. The treatment of histoplasmosis with fluconazole in patients with AIDS is examined in this multicenter, open-labeled, nonrandomized prospective trial. Various dosages were tested and it was concluded that fluconazole at 800 mg daily is moderately effective induction therapy for mild or moderately severe cases of histoplasmosis in the AIDS patient.
Hecht FM, Wheat J, Korzun AH, et al.: Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:100–107. This article takes a look at itraconazole 200 mg daily as a preventive measure in the relapse of disseminated histoplasmosis in HIV-patient. It concludes that itraconzole 200 mg daily is effective in preventing relapse and is generally well tolerated.
Graybill JR, Najvar LK, Montalbo EM, et al.: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother 1998 42:151–153.
Gomez FJ, Allendoerfer R, Deepe GS Jr: Vaccination with recombinant heat shock protein 60 from H. capsulatum protects mice against pulmonary histoplasmosis. Infect Immun 1995, 63:2587–2595.
Centers for Disease Control and Prevention: Blastomycosis-Wisconsin, 1986–1995. MMWR 1996, 45:601–603.
Baumgardner DJ, Brockman K: Epidemiology of human blastomycosis in Vilas County, Wisconsin. II: 1991–1996. Wisconsin Med J 1998 97:44–47.
Davies SF, Sarosi GA: Epidemiological and clinical features of pulmonary blastomycosis [review]. Semin Respir Infect 1997, 12:206–218.
Thompson CA, McEachern R, Norman JR: Blastomycosis as an etiology of acute lung injury. South Med J 1998, 91:861–863.
Mukkamala R, Mehta JB, Myers JW, Cole CP: Pulmonary blastomycosis with acute respiratory failure as predominant clinical feature. South Med J 1997, 90:847–850.
Pappas PG: Blastomycosis in the immunocompromised patient [review]. Semin Respir Infect 1997, 12:243–251.
Chao D, Steier KJ, Gomila R: Update and review of blastomycosis [review]. J Am Osteopath Assoc 1997, 97:525–532.
Chapman SW, Rogers PD, Rinaldi MG, Sullivan DC: Susceptibilities of clinical and laboratory isolates of B. dermatitidis to ketoconazole, itraconazole, and fluconazole. Antimicrob Agents Chemother 1998 42:978–980.
Pappas PG, Bradsher RW, Kauffman CA, et al.: Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1997, 25:200–205.
Clemons KV, Stevens DA: Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemoth 1997, 41:2026–2028. Nikkomycin Z is compared at various doses and treatment durations to amphotericin B and itraconazole in a murine model of pulmonary blastomycosis. The results indicated that nikkomycin Z is well tolerated, and has good activity against blastomycosis.
Wuthrich M, Chang WL, Klein BS: Immunogenicity and protective efficacy of the WI-1 adhesin of B. dermatitidis. Infect Immun 1998, 66:5443–5449.
Vaz A, Pineda-Roman M, Thomas AR, Carlson RW: Coccidioidomycosis: an update [review]. Hosp Pract 1998, 3:105–120.
Schneider E, Hajjeh RA, Spiegel RA, et al.:Coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA. 1997, 277:904–908. This study demonstrates a direct correlation between the disruption of soil, as seen in this Californian earthquake, and an increase in infections caused by C. immitis.
Ogiso A, Ito M, Koyama M, et al.: Pulmonary coccidioidomycosis in Japan: case report and review. Clin Infect Dis 1997, 25:1260–1261.
Zalatnai A, Zala J, Sandor G: Coccidioidomycosis in Hungary: the first import case. Pathol Oncol Res 1998, 4:147–151.
Burt A, Dechairo BM, Koenig GL, et al.: Molecular markers reveal differentiation among isolates of Coccidioides immitis from California, Arizona and Texas. Molec Ecol 1997, 6:781–786.
Kirkland TN, Fierer J: Coccidioidomycosis: a reemerging infectious disease [synopses]. Emerg Infect Dis 1996, 2:192–199.
Arsura EL, Bellinghausen PL, Kilgore WB, et al.: Septic shock in coccidioidomycosis. Crit Care Med 1998, 26:62–65. This article looks at the clinical and laboratory paramenters of septic shock in patients infected with C. immitis and offers guidelines for earlier diagnosis of this syndrome.
Fierer J, Walls L, Eckmann L, et al.: Importance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis. Infect Immun 1998, 66:4397–4402.
Holt CD, Winston DJ, Kubak B, et al.: Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997, 24:216–221.
Singh VR, Smith DK, Lawrence J, et al.: Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996, 23:563–568.
Chitkara YK: Evaluation of cultures of percutaneous core needle biopsy specimens in the diagnosis of pulmonary nodules. Am J Clin Pathol 1997, 107:224–228.
Koehler AP, Cheng AF, Chu KC, et al.: Successful treatment of disseminated coccidioidomycosis with amphotericin B lipid complex. J Infection 1998, 36:113–115.
Dewsnup DH, Galgiani JN, Graybill JR, et al.: Is it ever safe to stop azole treatment for Coccidioides immitis meningitits? Ann Intern Med 1996, 124:305–310.
Ampel NM, Dols CL, Galgiani JN: Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal area. Am J Med 1993, 94:235–240.
Clemons KV, Stevens DA: Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis. Antimicrob Agents Chemother 1997, 41:200–203.
Lutz JE, Clemons KV, Aristizabal BH, Stevens DA: Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997, 41:1558–1561.
Zimmermann CR, Johnson SM, Martens GW, et al.: Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules. Infect Immun 1998, 66:2342–2345.
Kirkland TN, Finley F, Orsborn KI, Galgiani JN: Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect Immun 1998, 66:3519–3522.
Broderick LS, Conces DJ, Tarver RD, et al.: Pulmonary aspergillosis: a spectrum of disease [review]. Crit Rev Diagn Imag 1996, 37:491–531.
Denning DW: Invasive Aspergillosis. Clin Infect Dis 1998, 26:781–805. An excellent state-of-the-art clinical article on the entire spectrum of invasive aspergillosis from its history to its treatment and prognosis.
Mylonakis E, Mileno MD, Flanigan T, et al.: Pulmonary invasive aspergillosis in patients infected with the human immunodeficiency virus: report of two cases. Heart Lung 1998, 27:63–66.
Rello J, Esandi M, Mariscal D, et al.: Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review—brief reports. Clin Infect Dis 1998, 26:1473–1475.
Kaiser L, Huguenin T, Lew PD, et al.: Invasive aspergillosis: clinical features of 35 proven cases at a single institution. Medicine 1998, 77:188–194.
Herrmann J, Gugel A, Freidank H, et al.: Aspergillus antigen detection: comparison of a new sandwich ELISA with the latex agglutination test in patients with histologicly proven invasive aspergillose. Mycoses 1998, 41(Suppl 1):83–85.
Logan PM, Muller NL: High-resolution computed tomography and pathologic findings in pulmonary aspergillosis: a pictorial assay. Can Assoc Radiol J 1996, 47:444–452.
Caillot D, Casasnovas O, Bernard A, et al.: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15:139–147.
Nikaido Y, Nagata N, Yamamoto T, et al.: A case of allergic bronchopulmonary aspergillosis successfully treated with itraconazole. Respir Med 1998, 92:118–124.
Salerno CT, Ouyang DW, Pederson TS, et al.: Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 1998, 65:1415–1419.
Stevens DA, Lee JY: Analysis of compassionate use of itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997, 157:1857–1862.
van Ôt Hek LG, Verweij PE, Weemaes CM, et al.: Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998, 157:1694–1696.
Denning DW: Echinocandins and pneumocandins—a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997, 40:611–614.
Verweij PE, Oakley KL, Morrissey J, et al.: Efficacy of LY303366 against amphotericin B susceptible and resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998, 42:873–878.
Espinel-Ingroff A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998, 36:2950–2956.
Bartroli J, Turmo E, Alguero M, et al.: UR-9,825: a new triazole derivative with potent, broad-spectrum antifungal activity. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1997:125.
Walsh TJ, Hiemenz JW, Seibel NL, et al.: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383–1396.
Ellis M, Spence D, de Pauw B, et al.: An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergilosis. Clin Infect Dis 1998, 27:1406–1412. This is the first completed prospective randomized clinical efficacy trial of antifungals in the treatment of invasive aspergillosis. This study compares the clinical efficacy of two doses of liposomal amphotericin B in immunosuppressed patients.
Wallace JM, Lim R, Browdy BL, et al.: Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary complications of HIV infection study group. Chest 1998, 114:131–137.
Mylonakis E, Barlam TF, Flanigan T, Rich JD: Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998, 114:251–262. Aspergillosis is still an uncommon infection in the HIV population. However, it is frequently fatal. This article reviews the typical symptoms, predisposing factors and diagnostic approaches.
Addrizzo-Harris DJ, Harkin TJ, McGuinness G, et al.: Pulmonary aspergilloma and AIDS: a comparison of HIV-infected and HIV-negative individuals. Chest 1997, 111:612–618. Aspergilloma has been reportedly relatively rarely in HIV disease. The impact of HIV on pulmonary aspergilloma is investigated. Risk factors are discussed.
Buchanan KL, Murphy JW: What makes Crytpococcus neoformans a pathogen? Emerg Infect Dis Synop 1998, 4:71–80. A very in depth look at the pathogenicity and virulence of C. neoformans and the realization that many questions still need to be answered.
Vinergarwala F, Graviss EA, Lacke CE, et al.: Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysisof predictive factors. Clin Infect Dis 1998, 27:1231–1237.
Miller KD, Mican JA, Davey RT: Asymptomatic solitary pulmonary nodules due to Cryptococcus neoformas in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:810–812.
Schubert S, Lebeau A, Zell R, Goebel F: Cavitary cryptococcoma of the lungs and meningitis by Cryptococcus neoformans in a patient with AIDS. Eur J Med Res 1997, 2(4):173–176.
Ramirez-Ortiz R, Rodriguez J, Soto Z, et al.: Synchronous pulmonary cryptococcosis and histoplasmosis. South Med J 1997, 90:729–732. The first reported case of concominant infection by Cryptococcus and Histoplasma.
Feldmesser M, Harris C, Reichberg S, et al.: Serum cryptococcal antigen in patients with AIDS [editorial]. Clin Infect Dis 1996, 23:827–830.
Williamson JD, Silverman JF, Mallak CT, Christie JD: Atypical cytomorphology appearance of Cryptococcus neoformans: a report of five cases. Acta Cytologica 1996, 40:363–370.
Wu J, Liao W, Chai J: Isolation of specific DNA probes for detection of Crytococcus neoformans. Mycoses 1997, 40:385–389.
Yamamoto Y, Maesaki S, Kakeya H, et al.: Combination therapy with fluconazole and flucytosine for pulmonary cryptococcosis. Chemotherapy 1997, 43:436–441.
van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Disease Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:1557–1558. The most common presentation of cryptococcosis in the HIV patient is meningitis. The cornerstone of treatment has been amphotericin B alone. This study compares amphotericin B with and without flucytosine and looks at consolidation therapy.
de Lalla F, Pellizzer G, Vaglia A, et al.: Amphotericin B as primary herapy for Cryptococcus in patients with AIDS: reliability of relatively high doses administred over a relatively short period. Clin Infect Dis 1995, 20:263–266.
Leenders AC, Reiss P, Portegies P, et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDSassociated cryptococcal meningitis. AIDS 1997, 11:1463–1471.
Orendi JM, Verheul AF, De Vos NM, et al.: Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication. Clinic Exper Immunol 1997, 107:293–299.
Harrison TS, Nong S, Levitz SM: Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J Infect Dis 1997, 176:485–491.
Delfino D, Cianci L, Lupis E, et al.: Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect Immun 1997, 65:2454–2456.
Vecchiarelli A, Monari C, Retini C, et al.: Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur J Immunol 1998, 28:114–121.
Monari C, Retini C, Palazzetti B, et al.: Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin Exp Immunol 1997, 109:242–247.
Carillo-Munoz AJ, Tur-Tur C: Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy 1997, 43:387–392.
Nguyen MH, Yu CY: In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998, 42:471–472.
Lamb DC, Baldwin BC, Kwon-Chung KJ, et al.: Stereoselective interaction of the azole antifungal agent SCH39304 with the cytochrome P-450 monooxygenase system isolated from Cryptococcus neoformans. Antimicrob Agents Chemother 1997, 41:1465–1467.
Tortorano AM, Viviani MA, Rigoni AL, et al.: Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy. Mycoses 1997, 40:297–302.
Levtitz SM, Harrison TS, Tabuni A, Liu X: Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest 1997, 100:1640–1646.
Feldmesser M, Kress Y, Casadevall A: Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J Infect Dis 1998, 177:1639–1646.
Casadevall A, Cleare W, Feldmesser M, et al.: Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 1998, 42:1437–1446.
Coffey MJ, Phare SM, George S, et al.: Granulocyte colonystimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activitiy in neutrophils. J Clin Invest 1998, 102:663–670.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jacobs, A.V., Leaf, H.L. Fungal infections of the lung. Curr Infect Dis Rep 1, 89–98 (1999). https://doi.org/10.1007/s11908-999-0015-5
Issue Date:
DOI: https://doi.org/10.1007/s11908-999-0015-5